A Phase I Study of Dovitinib (TKI258) in Combination with Gemcitabine and Capecitabine in Advanced Solid Tumors, Pancreatic and Biliary Cancers

This is a single-arm, open-label, phase 1 dose-escalation study of dovitinib in combination with gemcitabine and capecitabine and has 2 parts. The Primary objective are to determine the maximum tolerated dose and recommended phase 1 dose of dovitinib when administered concurrently with gemcitabine and capecitabine in patients with advanced solid malignancies and to characterize then safety profile of dovitinib, gemcitabine, and capecitabine combination in patients with advanced solid malignancies.

Study Number: 

I 175610

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.